Why the dose schedule cannot be rushed Clinical trial data from the phase 2 NEJM study revealed something critical about dose scheduling
Ozempic is FDA-approved for type 2 diabetes but also supports weight loss as a side benefit
If semaglutide (single agonist) is first generation, and tirzepatide and mazdutide (dual agonists) are second generation, then retatrutide (triple agonist) is the beginning of the third generation
As with all good research reports, this one finally turns to "what does this all mean?" And interestingly, the researchers (two of whom work in Cornell's business school) chose to adopt the perspective of stakeholders in the food industry, pointing out that broad-based reductions in household food expenditures have implications for grocery chains, restaurants, and the businesses that grow and make food
Initial consumer insights on GLP-1 drugs from global market intelligence company Mintel shows that two camps are quickly forming: those open to utilising the drugs to manage weight and those who have no interest in the drugs but who want the benefits that come with the drugs
Phase three is integration: synthesizing the legal, scientific, and regulatory findings into a financial model, identifying deal structure implications, and producing the deliverable that corporate development and the investment committee will use
